Finch Therapeutics Group (NASDAQ: FNCH) reported Q4 2023 earnings per share (EPS) of -$1.89, up 88.82% year over year. Total Finch Therapeutics Group earnings for the quarter were -$3.04 million. In the same quarter last year, Finch Therapeutics Group's earnings per share (EPS) was -$16.90.
As of Q2 2024, Finch Therapeutics Group's earnings has grown year over year. Finch Therapeutics Group's earnings in the past year totalled -$74.75 million.
What was FNCH's revenue last quarter?
Finch Therapeutics Group (NASDAQ: FNCH) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Finch Therapeutics Group's revenue was $8.00 thousand.
What was FNCH's revenue growth in the past year?
As of Q2 2024, Finch Therapeutics Group's revenue has grown -87.57% year over year. This is 233.3 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Finch Therapeutics Group's revenue in the past year totalled $107.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.